Quick Answer
Akari Therapeutics Plc reported Total Assets of $47.89 million for the year ending 2025.
- Akari Therapeutics Plc showed a decrease of -5.3% in Total Assets from 2024 to 2025.
- This data is from Akari Therapeutics Plc's annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2012 to 2025 (20 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: $4.32 million | Q2 2015: $2.96 million | Q3 2015: $79.17 million | Q1 2016: $62.96 million | Q1 2024: $2.77 million | Q2 2024: $5.08 million | Q3 2024: $2.73 million | Q1 2025: $50.96 million | Q2 2025: $50.91 million | Q3 2025: $45.38 million.
- Over the full 20 years of available data (2012 to 2025), Akari Therapeutics Plc's Total Assets has grown by 4,176.1%.
- Historical annual values: Fiscal year 2025: $47.89 million | Fiscal year 2024: $50.56 million | Fiscal year 2023: $4.36 million | Fiscal year 2022: $13.83 million | Fiscal year 2021: $11.65 million | Fiscal year 2020: $14.60 million | Fiscal year 2020: $13.69 million | Fiscal year 2020: $14.45 million | Fiscal year 2020: $9.68 million | Fiscal year 2019: $6.48 million | Fiscal year 2019: $10.27 million | Fiscal year 2019: $4.61 million | Fiscal year 2019: $8.23 million | Fiscal year 2018: $8.03 million | Fiscal year 2017: $29.05 million | Fiscal year 2016: $45.87 million | Fiscal year 2015: $69.89 million | Fiscal year 2014: $3.39 million | Fiscal year 2013: $7.83 million | Fiscal year 2012: $1.12 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: